Opinion|Videos|September 24, 2024
Role of MRAs in HFmrEF and HFpEF
Author(s)Javed Butler, MD, MPH, MBA
Javed Butler, MD, MPH, MBA, discusses the current mineralocorticoid receptor antagonists (MRAs) used for heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, emphasizing the role of nonsteroidal MRAs such as finerenone, and explore how the FINEARTS-HF results could translate into real-world benefits and inform the clinical pathway for these patients.
Advertisement
Video content above is prompted by the following:
- Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure with preserved EF (HFpEF), and what role does a nonsteroidal MRA such as finerenone have to offer in this treatment landscape based on the results of FINEARTS-HF?
- How might these results translate into real-world benefit, and where do you see their place in the clinical pathway for patients with HFmrEF or HFpEF?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5
